

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

12-01167-02

Docket or Reference number

030-01394

Amendment No. 45

St. Francis Hospital
530 N.E. Glen Oak
Peoria, IL 61637

In accordance with application dated July 23, 1983, License Number 12-01167-02 is amended as follows:

Subitems 6.F., 7.F., 8.F. and 9.F. are deleted.

Subitem 9.I. is amended to read:

9. Authorized Use

I. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

Conditions 12. and 19. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

R.V. Kowalski, M.D.

Groups I, II and III
In vitro studies
Xenon-133

J.P. McGowan, M.D.

Groups I and II
In vitro studies
Xenon-133

B.C. Berg, Jr., M.D.

All, except Group VI

R. W. Meyers

In vitro studies

David P. Walker, M.D.

Group VI

William A. Shipley, M.D.

All

Thomas J. Cusack, M.D.

Groups I, II, III, IV and V
In vitro studies
Iodine-125 in diagnostic bone scanner

Clinton J. Wentz, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies
Iodine-125 in diagnostic bone scanner

John A. Zimdars, M.D.

All

8512030009 850907
REG3 LIC30
12-01167-02 PDR

11 COPY mlz
BS 9/10/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
12-01167-02

Docket or Reference number
030-01394

Amendment No. 45

Gordon T. Campbell, M.D.

Groups I, II, III and V
Xenon-133
Phosphorus-32 in soluble form for
treatment of polycythemia vera,
leukemia and bone metastases
Iodine-131 for therapy
Iodine-125 for diagnostic bone
scanner

Charles W. Keiser, M.D.

Groups I, II and III
Xenon-133
Iodine-131 for treatment of
hyperthyroidism
In vitro studies

Irving J. Weigenberg, M.D.

Group VI

B. R. Roger, M.D.

Group VI

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated October 6, 1983, August 16, 1983 (except Item No. 15), April 13, 1984, July 24, 1984, November 13, 1984 and July 24, 1985; ALARA Program dated August 16, 1983; letters dated May 22, 1984 and September 6, 1984; and mailgram dated July 18, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Original Signed

By William J. Adam, Ph.D.

Materials Licensing Section, Region III

Date September 9, 1985

COPY